摘要
目的了解不同时期艾滋病抗病毒治疗患者初治及经治ART方案的使用情况,分析不同药物组合的换药情况及换药原因。方法选取2017年1月至2022年6月初始入组ART的患者纳入研究,分析不同时期入组者人口学特征及初治与经治ART方案的变化,同时比较不同方案的换药率差异。结果研究对象以男性为主,平均年龄(41.35±14.2)岁,且有增大的趋势(P<0.001)。初治患者ART方案以TDF/AZT+3TC+EFV为主,而治疗后使用率有所下降。换药率以TDF+3TC+EFV方案最高(17.3%);含LPV/r的方案使用率与初治时相比有增加;含整合酶的方案在2021年和2022年初治患者中增加明显(P<0.001)。换药率在治疗1 a、2 a、3 a、4 a、5 a间没有差异(P=0.376)。换药原因主要为药物副作用(57.4%)。结论ART药物的选择由核苷非核苷类逐渐向整合酶抑制剂转换,更趋向于个体化,结合患者的临床特点及合并症选择最适合患者的高效、低毒、简便的方案更有利于患者长期有效的治疗。
Objective To understand the use of primary and menstrual ART regimens for HIV patients receiving antiviral treatment in different periods,and to analyze the dressing change situation and reasons of different drug combinations.Methods Patients initially enrolled in ART from January 2017 to June 2022 were included in the study.The demographic characteristics and the changes of the primary and menstrual ART regimens of the participants in different periods were analyzed and the differences in dressing change rates between the different regimens were compared.Results Most of the subjects were male,The average age was 41.35±14.2 years old and there was an increasing trend(P<0.001).TDF/AZT+3TC+EFV was the main ART regimens in newly diagnosed patients,but the utilization rate decreased after the treatment.The TDF+3TC+EFV regimen had the highest dressing change rate(17.3%).Compared with the initial treatment,the utilization rate of the protocol containing LPV/r increased.Integrase-containing regimens increased significantly in the treated patients in 2021 and early 2022(P<0.001).Drug change rates did not differ at 1,2,3,4,and 5 years of treatment(P=0.376).The main reason for dressing change was drug side effects(57.4%).Conclusion The selection of ART drugs gradually switches from nucleoside and non-nucleosides to integrase inhibitors.The choice of ART drugs is gradually changing from the nucleoside non-nucleoside to integrase inhibitor,which tends to be individualized.Combining the clinical characteristics and complications of patients and choosing the most efficient,low-toxic and simple scheme are more conducive to the long-term effective treatment of patients.
作者
田波
李重熙
金永梅
关玮
陈海云
刘俊
TIAN Bo;LI Chongxi;JIN Yongmei;GUAN Wei;CHEN Haiyun;LIU Jun(The Third People’s Hospital of Kunming/Yunnan Clinical Medical Center for Infectious Diseases.Kunming Yunnan 650041,China)
出处
《昆明医科大学学报》
CAS
2023年第5期162-167,共6页
Journal of Kunming Medical University
基金
云南省科技厅地方高校联合专项基金资助项目(202001BA070001-194)
昆明市卫生科技基金资助项目(2022-03-08-013,2022-03-08-007)。
